Objective: To determine whether oestrogen receptor (ER)a messenger RNA (mRNA) levels or single nucleotide polymorphisms (SNPs) are associated with obesity in Swedish women. Design: ERa mRNA expression levels were measured by real-time qPCR in subcutaneous adipose tissue from non-obese (N ¼ 16, BMI o30) and obese (N ¼ 17, BMI X30) women. In addition, ERa mRNA expression levels were determined in isolated adipocytes. ERa promoter usage was characterized by 5 0 RACE and by real-time qPCR in subcutaneous adipose tissue from the same non-obese and obese women. Two ERa SNPs were scored in 509 non-obese and 489 obese females. Results: ERa mRNA expression levels were lower in obese compared to non-obese women in both subcutaneous adipose tissue and in adipocytes. We show that two ERa promoters are differentially utilized in obese and non-obese individuals. We did not find any significant association between obesity and the ERa SNPs or haplotypes assayed. Conclusion: The reduced ERa mRNA levels observed in adipose tissue from obese compared to non-obese women support a role for oestrogen signaling via ERa, in control of body weight. Mechanistic studies of the role of ERa in adipocytes and how its expression is regulated in relation to fat mass should be performed. The latter studies should focus on the two promoters that are used differently in obese and non-obese individuals.
Introduction
Obesity represents a major health problem. Both genetic and environmental factors contribute to its development 1 and several genes seem to be involved. 2 The oestrogen receptors (ERs) are ligand-activated transcription factors that belong to the nuclear receptor superfamily. 3 After activation by their cognate ligands, the oestrogens, the receptors influence diverse processes throughout the body. Two different ERs have been described, namely ERa and ERb. [4] [5] [6] Several ER variants exist, for example ERa46, an N-terminally truncated variant of ERa that is the product of translational initiation at an internal ATG site. 7 ER mRNAs are expressed in mature human adipocytes where the ERa mRNA predominates. 8 ERa mRNA levels do not differ in adipocytes from different anatomical origins (intraabdominal or subcutaneous) or according to gender in non-obese individuals. 8 Women usually increase their body weight after menopause when oestrogen levels naturally decrease. 9 Postmenopausal women tend to shift to an android fat distribution with increased visceral and central fat depots. 10, 11 This could reflect reduced oestrogen levels and/or a relative increase in testosterone, following cessation of oestrogen production in the ovaries. 12 A role of oestrogen in maintenance of body weight is supported by the observation that central adiposity is prevented in women given hormone replacement treatment (HRT). [13] [14] [15] Furthermore, lower body weight and waist circumference were also seen after treatment with oestrogen and progestin compared to placebo in the Women's Health Initiative Study. 16 Another study however, failed to show any connection between HRT and body fat distribution or body composition. 17 Further support for a role of oestrogen signaling (particularly via ERa) in relation to body weight is the obese phenotype observed in ERa knockout (ERKO) mice. [18] [19] [20] Moreover, genome-wide linkage analysis identified a locus linked to body mass index (BMI) at chromosome 6q23-25 with a peak LOD score of 4. 6 . 21 This region contains the ERa gene. Factors determining waist circumference were subsequently linked to the same region with a peak LOD score of 3.7.
22
A previous study investigating association between ERa single nucleotide polymorphisms (SNPs) rs2234693 and rs9340799 and body fat distribution in Japanese subjects showed that the rs2234693 GG genotype contributes to the development of upper-type obesity in middle-aged female individuals but that it may be associated with both decreased whole-body fat tissue and abdominal fat tissue in older individuals. 23 No such associations were apparent in male subjects. However, in a recent study, obesity phenotypes were found to be associated with ERa polymorphisms in men predominantly of Caucasian origin. 24 In this study, we investigate whether ERa mRNA levels and/or the two SNPs rs2234693 and rs9340799 are associated with obesity in Swedish women.
Methods

Subjects
For ERa mRNA measurements in subcutaneous adipose tissue, healthy subjects from the Stockholm area were consecutively recruited by local advertizing for studies on metabolic regulation in fat cells. All subjects were of Swedish origin. We studied non-obese (N ¼ The women came to the laboratory in the morning after an overnight fast. A venous blood sample was obtained for extraction of DNA and determination of serum insulin, as well as plasma glucose, triglycerides, total cholesterol and HDL cholesterol as described. 26, 27 Insulin resistance index HOMA IR was calculated as fasting serum insulin (mU/ ml) Â fasting plasma glucose (mmol/l)/22.5.
28
Needle biopsies of abdominal subcutaneous adipose tissue (1-2 g) were obtained under local anaesthesia in the morning after an overnight fast. Adipose tissue was treated with collagenase for isolation of adipocytes as previously described. 29 Adipose tissue pieces and isolated adipocytes were frozen in liquid nitrogen and stored at À801C for later RNA preparation. The study was approved by the local ethical committee at the Karolinska University Hospital. It was explained in detail to each participant and her written consent was obtained.
RNA isolation and cDNA synthesis Total RNA was prepared from human adipose tissue and adipocytes using the RNeasy mini kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions. RNA samples were treated with RNase-free DNaseI (Qiagen). Total RNA was reverse transcribed into cDNA employing either oligo dT 30 or random hexamer primers using the Omniscript RT kit (Qiagen). Oligo dT primers were used for the isolated adipocytes and the weight reduced individuals. High-quality RNA was ensured using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palp Alto, CA, USA).
Real-time quantitative PCR
ERa mRNA expression levels were quantified by Taqman assays with two sets of primers targeting the ERa exon 3 and 4 boundary, and the 3 0 UTR, respectively. These are referred to as ERa 5 0 and ERa 3 0 UTR and their locations are indicated in Figure 1 . SYBRgreen assays were used to assay ERa promoters and the internal control genes, 18S, GAPDH and b2-microglobulin. All qPCR assays were run on an ABI 7500 machine (Applied Biosystems, Foster city, CA, USA). A direct comparative method was used for data analysis (User Bulletin #2, Applied Biosystems). All primers were designed with the Primer Express Software version 2.0, a program specially provided for primer design using ABI qPCR machines. For each pair of SYBRgreen assay primers, a dissociation curve analysis was conducted to ensure the specificity of the PCR amplification. Primer/probe sequences were as follows: ERa 5 0 (F: 5 0 -GCTACGAAGTGGGAATGAT Decreased ERa mRNA expression levels in obesity M Nilsson et al GAAAG-3 0 ; R: 5 0 -TCTGGCGCTTGTGTTTCAAC-3 0 ; and Taqman probe:
0 ; and Taqman probe: . The primers were also used in other combinations to check for splicing between exons. All realtime qPCR reactions were performed in triplicates.
Only polydT primed cDNA samples were available from the isolated adipocytes and from the individuals before and after gastric banding. As the 3 0 UTR region of human ERa is very long, we were only able to detect ERa transcripts using qPCR primers located in the 3 0 UTR in these samples. Also, these specific samples were not normalized to 18S. As the 18S transcript contains no conventional poly-A sequence, it was not included as a control gene for these samples. were used to amplify promoter transcripts according to the manufacturer's instructions. The PCR products were gel purified and ligated into a pGEM T Easy-vector (Promega, Madison, WI, USA). Ligations were transformed into competent bacteria and plated onto appropriate antibiotic containing plates from which colonies were inoculated and DNA minipreps made by standard protocol. DNA sequencing confirmed the identities of all clones.
Western blot analysis Differentiation of human preadipocytes was performed as previously described by Dicker et al. 12 Briefly, cells were isolated from the stromavascular fraction of collagenasetreated adipose tissue obtained from obese, otherwise healthy donors. Cells were differentiated in 22 mm wells using a defined serum-free culture medium supplemented with 10 mmol/l rosiglitazone and 0.2 mmol/l 3-isobutyl-1-methylxanthine (IBMX) for 3 days and maintained in culture medium without rosiglitazone and IBMX until the end of differentiation. The cells were investigated at day 15. Protein was isolated by lysing cells in 1% Triton -X-100, Tris-HCL pH 7.6, 150 mM NaCl supplemented with protease inhibitors (Complete, Roche, Basel, Switzerland and 1 mmol/ l PMSF). The cell lysate was centrifuged at 14 000 rpm for 30 min and the infranatant removed and saved. All steps were performed at 41C to minimize the risk of protein degradation. The protein content was quantified using the Bio-Rad Protein Assay Kit (Bio-Rad, Hercules, CA, USA, Cat. expression levels in non-obese and obese individuals assayed by real-time qPCR using a primer pair located within the gene (Po0.00003) using 18S as internal control gene. Significant differences were also seen using either GAPDH or b2-microglobulin as normalization genes (results not shown). (b) ERa gene expression levels in non-obese and obese individuals assayed by real-time qPCR using a primer pair located in the 3 0 UTR (Po0.001) using 18S as internal control gene. Significant differences were also seen using either GAPDH or b2-microglobulin as normalization genes (results not shown). Values are average7s.e.m. Nominal Pvalues o0.05 are considered significant. **Po0.01 (c)
No. 500-0006) according to the manufacturer's instructions and 100 mg was used in Western blot analysis. As positive control for the full-length ERa protein, we used whole-cell extracts from MCF7 breast carcinoma cells transiently transfected with the pSG5 vector expressing the wild-type human ERa cDNA (pSG5-ERa). As positive control for the 46 kDa ERa form (pSG5-ERKO), we used a variant originally identified in a male with mutated ERa. 31 This mutation generates a premature stop codon at amino-acid position 157 of ERa and is suggested to generate an ERa 46 kDa form owing to translation initiation from an internal ATG. The ERa mRNA species starting 3 0 of the common ATG identified in our studies would be expected to initiate translation at this ATG. The mutation was introduced with the QuikChange XL site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA), with pSG5-ERa as template, using the primer 5 0 -CCAAATTCAGATAATT GACGCCAGGGTGGC-3 0 and its corresponding reverse complement, with the point mutation being underlined. 1 mg DNA template was in vitro translated in a 50 ml reaction using the TNT Coupled Reticulocyte Lysate Systems (Promega). Two microlitres of this reaction was used in Western blot analysis.
Protein extracts were subjected to 12% SDS-PAGE and transferred to Hybond-P membrane (Amersham) by standard techniques. The membrane was blocked for 1 h at room temperature in PBS-T (PBS þ 0.1% Tween 20) complemented with 5% milk powder. The membrane was incubated with the primary antibody (HC-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA, sc-543) over-night at 41C in PBS-T with 5% milk powder and subsequently washed 3 Â 10 min in PBS-T. The primary antibody was detected using horseradish peroxidase-linked anti-rabbit secondary antibody with the SuperSignal West Pico Chemiluminescent Substrate detection kit (Pierce Biotechnology, Rockford, IL, USA).
ERa rs2234693 and rs9340799 genotyping
The DNA samples were genotyped for ERa single nucleotide polymorphisms SNPS rs2234693 and rs9340799 using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (Sequenom Inc.) as described previously. 32 Primers are provided on request.
Linkage disequilibrium between adjacent markers and haplotypes were estimated using SNPHAP and attached programs (http://archimedes.well.ox.ac.uk/pise/snphap-simple. html).
Statistical analysis
ERa mRNA levels were compared between non-obese and obese women by Student's t-test. w 2 test was used to determine whether genotype and haplotype frequencies differed between affected and non-affected individuals.
Results
ERa mRNA expression levels are lower in adipose tissue and adipocytes from obese compared to normal weight individuals Using qPCR we determined ERa mRNA expression levels in adipose tissue from 16 non-obese and 17 obese women. Figure 1 shows that ERa expression levels are significantly lower in obese compared to non-obese women (P-value o0.001). These differences in ERa expression levels were observed using two different primer/probe sets (Figure 1a and b).
To determine whether differences in ERa mRNA levels observed between non-obese and obese women in adipose tissue biopsies were owing to differences in ERa mRNA levels in adipocytes, we analyzed mRNA levels in isolated adipocytes from non-obese (N ¼ 5) and obese women (N ¼ 9). This analysis confirmed that ERa mRNA was reduced in isolated adipocytes from obese women compared to non-obese women (Figure 2 ; P-value ¼ 0.037).
To further substantiate the correlation between obesity and reduced ERa expression level, we analysed ERa mRNA expression levels in obese women before and after weight reduction following gastric banding. Figure 3 shows that ERa mRNA expression levels increased after caloric energy restriction in a majority of cases.
Analysis of ERa gene promoter usage in human adipocytes
Several ERa promoters have been identified as summarized in Figure 4a , adapted from Kos et al. 33 and Okuda et al. 34 Two approaches were used to identify ERa promoter usage. First, 5 0 RACE was used as a non-biased approach to identify active promoters. Second, real-time quantitative PCR was used to determine promoter usage in our subjects, by assaying transcription from previously described exons upstream of the ATG site coding for the characterized full length receptor protein.
Using 5 0 RACE, transcripts from promoters C and F were detected in the Human Adipocyte Marathon-Ready cDNA (Figure 4b ). Several transcripts were identified that start in exon E2 indicating the presence of a promoter upstream of E2. Also, transcripts starting 3 0 of the ATG coding for the characterized full-length receptor protein were detected. These transcripts suggest the generation of the shorter 46 kDa form of ERa in human subcutaneous fat. 7 In accordance with this, Western blot analysis of protein extracts from differentiated human adipocytes showed the presence of ERa protein variants of 66 and 46 kDa, respectively ( Figure 5 ). Using real-time quantitative PCR, we detected transcripts from the untranslated exons A, C and E2 in all individuals (Figure 4c ), whereas transcripts from the B, D, E1, and T exons were not detected (Figure 4c ). Transcripts from untranslated exon F were detected in some but not all individuals. These data support the RACE data above in suggesting that a previously unidentified promoter, located Decreased ERa mRNA expression levels in obesity M Nilsson et al upstream of exon E2, is expressed in adipocytes. Transcription from potential promoters residing down-stream of the characterized full-length receptor ATG, which was suggested by the RACE analysis above, was not assayed in these samples.
Transcripts originating from promoters C and E2 are specifically reduced in subcutaneous adipose tissue from obese compared to non-obese individuals Interestingly, when comparing promoter usage between obese and non-obese individuals, transcripts originating from promoters C and E2 are reduced in obese compared to non-obese individuals (Po0.015 and Po0.03, respectively), whereas no significant difference was found for transcripts originating from promoter A (Figure 6 ). There were no differences in the levels of exon F transcripts between non-obese and obese individuals when levels of this transcript were assayed in the subset of individuals where it was detected (data not shown).
ERa SNPs are not associated with obesity ERa SNPs rs2234693 and rs9340799 were genotyped in 998 women. Call rate in genotyping was 99% for rs2234693 and 95% for rs9340799. The alternative genotypes of each SNP were in Hardy-Weinberg equilibrium. rs2234693 and rs9340799 alleles displayed strong linkage disequilibrium (D 0 ¼ 0.99) and together defined three common haplotypes (Table 1) . Neither the rs2234693 and rs9340799 genotype frequencies (Table 2) , nor haplotype frequencies (Table 1) differed between non-obese and obese subjects. ERa expression levels before and after weight reduction, respectively. Sample 1A is arbitrarily set to one and all other values are relative to this sample. ERa mRNA levels were normalized to both b2-microglobulin (shown) and GAPDH with similar results.
Decreased
Discussion
Previous studies in humans have suggested a protective effect of oestrogen against body weight increase. In this study, we demonstrate that mRNA levels of ERa were inversely correlated to body weight in premenopausal Decreased ERa mRNA expression levels in obesity M Nilsson et al women. The negative correlation between ERa mRNA levels and obesity was confirmed in isolated adipocytes. Consistent with the differences in ERa expression levels between nonobese and obese women, ERa expression levels increased in females after weight reduction owing to gastric banding surgery. These data confirm previous gene expression profiling results in which ERa was upregulated in adipose tissue from females following modest weight reduction subsequent to energy-restricted diets. 35 We speculate that reduced levels of ERa in premenopausal women have the same effect on body weight as the reduction in oestrogen levels following menopause. However, our data do not conclusively allow us to determine whether reduced ERa mRNA level is a cause or a consequence of obesity in this group of women. It is important to consider that adipocyte ERa mRNA could be subject to regulation by oestrogen, the concentration of which might be correlated to body weight. It has been demonstrated that oestrogen treatment of isolated human subcutaneous adipocytes in vitro upregulates both ERa and b mRNA. 8 However, the relation between oestradiol levels and BMI is unclear. It has been reported that systemic oestradiol levels are negatively correlated with BMI. 36 However, a recent study demonstrated a positive correlation between oestradiol levels and body weight. 37 Therefore, we cannot predict the effect of BMI on oestrogen and ERa mRNA levels in our sample of women. Unfortunately, we do not have access to information about circulating oestrogen levels in the individuals investigated here. Clearly, additional studies are needed to clarify the relation between BMI, systemic and local oestrogen concentrations and ERa mRNA levels in human adipocytes. Our data suggest expression from two previously described ERa promoters in our subjects, namely promoters A and C, but also from a novel promoter, E2. Additionally, the previously characterized promoter F was expressed in some individuals. Using RACE analysis, we demonstrated transcription from promoters C and F, and this assay also suggested the existence of a novel promoter, E2. Differences in promoter usage identified with RACE and real-time qPCR, might depend on differences in the samples used for RACE analysis and our sample of obese and non-obese women, respectively, including different genetic background. Our data also indicate that there are transcripts starting 3 0 of the common translational start site ATG. These transcripts are consistent with the generation of the shorter 46 kDa form of ERa in subcutaneous fat. 7 Interestingly, both ERa66 and ERa46 were present in differentiated human adipocytes as shown by Western blot analysis. ERa46 lacks the N-terminal AF-1 transactivation domain and heterodimerizes with ERa66, thereby inhibiting transactivation of genes that depend on ERa AF1 for maximal activity. 7 Of the three active promoters identified in subcutaneous adipose tissue, two showed higher expression levels in nonobese individuals. These promoters will be the targets for further studies aimed at characterizing regulation of ERa in adipocytes.
No differences in genotype or haplotype frequencies of ERa SNPs rs2234693 or rs9340799 were detected between non-obese and obese subjects in this study. This is consistent with a recently published paper in which four ERa SNPs were analyzed in the Framingham Heart Study offspring cohort and where no association was found between these SNPs and markers of adiposity in women. 24 In conclusion, the reduced ERa mRNA levels observed in adipocytes from obese compared to non-obese individuals suggest that oestrogen signaling, in particular via ERa, may influence body weight. This warrants studies of the role of ERa in adipocytes and how its expression is regulated in relation to fat mass. Such studies should target the two promoters that displayed differential regulation between obese and non-obese individuals in this study. Decreased ERa mRNA expression levels in obesity M Nilsson et al
